《大行報告》大摩:現判斷中國生科板塊轉向仍尚早 但逆風減弱
大摩發表報告指,現判斷中國生科板塊轉向仍為時尚早,但逆風減弱。由於中國生科板塊今年開局表現波動,更新對今年餘下時間內中國生科行業的看法,並預計在6月美聯儲轉向(Fed Pivot)後,信達生物(01801.HK)和康諾亞-B(02162.HK)等優質成長型企業將首先出現估值重估。
大摩認為,香港上市生物科技指數的估值溢價已經下降,市場預期已經調整。但是行業增長放緩、內地債務和通縮風險,以及美聯儲轉向的流動性恢復,可能會在今年對中國生物技術領域構成挑戰。
另外,報告提到,全球化前景仍不明朗,多款美國新藥上市值得關注,今年將是國內生科行業的關鍵測試。 由於預計近期的出海創新藥在推動股價方面主要是早期階段和增量性質,市場將重點關注中國生科和製藥公司在美國市場的眾多商業上市表現。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.